Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt.

Cytochroma P450 CYP3A4 (-atis, n.) (Numerus EC: 1.14.13.97) est haemoproteinum et pars gregis Cytochroma P450 ideo in metabolismo xenobioticorum interest. CYP3A4 maxime omnium cytochromatum iecoris humani exprimatur[1].

Cytochroma P450 CYP3A4.

Locus recensere

Pharmaca ad CYP3A4 relata recensere

Multa chemotherapeutica, analgetica, cardiaca, psychopharmaca substratum cytochromatis 3A4 sunt. Inhibitores ut proteasis inhibitores (SCDI!) effectus substratorum augere possunt.

Pharmaca relata ad CYP3A4[2][3].
Substrati Inhibitores[4] Inductores[5]
  • Anticonvulsiva
    • Carbamazepinum (forte, quoque P-gp)
    • Phenytoinum (forte)
    • Fosphenytoinum (forte)
    • Oxcarbazepinum (forte)
    • Eslicarbazepinacetatum
    • Topiramatum
    • Phenobarbitalum (forte)
    • Primidonum (forte)
  • Antidepressiva
    • Hypericum perforatum (forte, quoque P-gp)
  • Antihypertensiva
    • Bosentanum (forte, endothelini receptoris inhibitor)
  • Substantiae antiretrovirales
    • Efavirenzum (forte)
    • Etravirinum (forte)
    • Nevirapinum (forte)
  • Substantiae antineoplasticae
    • Dabrafenibum
    • Enzalutamidum
    • Mitotanum (forte)
  • Antibiotica
    • Rifabutinum (forte)
    • Rifapentinum (forte)
    • Nafcillinum (forte)
    • Rifampicinum (forte)
  • Hormonta
    • Triiodthyroninum (T3)
  • Antiandrogena
    • Apalutamidum
  • Modafinilum
  • Quercetinum
  • Capsaicinum

Notae recensere

  1. Liddle, C; Goodwin, BJ; George, J; Tapner, M; Farrell GC (July 2003). "Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes". J Clin Endocrinol Metab 83 (7): 2411-6 
  2. Cozza KL, Armstrong SC (2001). The Cytochrome P450 System. Drug Interaction Principles for Medical Practice. Washington, DC: American Psychiatric Publishing
  3. Preskorn SH (1996). Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors. 1st ed.: Professional Communications, Inc.
  4. Inhibitor cum subtratorum effectibus fortioribus
  5. Inductor cum subtratorum effectibus minoribus
  6. Yuji Horikiri; Takehiko Suzuki; Masakazu Mizobe (March 1998). "Pharmacokinetics and metabolism of bisoprolol enantiomers in humans". Journal of Pharmaceutical Sciences 87 (3): 289–294 
  7. Gandhi S, Fleet JL, Bailey DG, McArthur 4, Wald R, Rehman F2, Garg AX (dec 2013). "Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury". JAMA 18 (23): 2544-53 
  8. Kronbach, T; Fischer, V; Meyer UA (June 1988). "Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs.". Clin Pharmacol Ther 43 (6): 630-5 
  9. Labroo RB, Thummel KE, Kunze KL, Podoll T, Trager WF, Kharasch ED (1995). "Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism". Drug Metab Dispos 23 (4): 490-6 
  10. 10.0 10.1 Apixabanum et Rivaroxabanum / P-gp et inductores fortes CYP3A4 (Anglice)
  11. Apixabani interactionum effectus (Anglice)

Nexus externi recensere